Friday 19th November 2004

SESSION 9:
DNA VACCINES PROCESSING/MANUFACTURING

Moderator:
Clive Dix (PowderMed, UK)

08.30-09.00
‘Large scale GMP plasmid DNA production, formulation and characterization’
M. Marquet, R. Musil, R. Hancock (Althea Technologies Inc., San Diego, USA)

09.00-09.15
‘Chromatographic methods to obtain highly enriched supercoiled DNA’
L.H. Smiley, J. Ballantyne (ProMetic Biosciences Inc./Aldevron LLC, USA)

09.15-09.30
‘Large scale CGMP production of plasmid DNA’
J. Urthaler, R. Necina, W. Buchinger (Boehringer-Ingelheim, Vienna, Austria)

09.30-09.45
‘Commercialization of DNA vaccines for aquaculture – Opportunities and constraints’
M. Roth, M. Horne, K. Salonius, G. Greenham (Aqua Health Ltd, Canada)

09.45-10.15
‘Non-chromatographic approach for the economical pharmaceutical-scale production of DNA vaccines’
Saneetha Sagar (Merck & Co. Inc., West Point, USA)

10.15-10.30
Coffee Break

10.30-10.45
‘Downstream processing of supercoiled plasmid DNA’
M. Sparrman, L.M. Sandberg, A. Andersson, J. Vasi, E. Hakansson, P. Nilsson, R. Lemmens (GE Healthcare, Uppsala, Sweden)

10.45-11.00
‘Animal-free plasmid DNA vaccines’
Martin Schleef, Carsten Voss, Torsten Schmidt (Plasmid Factory GmbH, Bielefeld, Germany)

11.00-11.20
‘Innovations in process technology for plasmid DNA manufacturing – Modular variations of a generic process, regulatory relevance and economic impact’
Joachim Schorr (Qiagen GmbH, Hilden, Germany)

11.20-11.35
‘Analytical and biological characterization of supercoiled plasmid produced by 4 chromatographic methods’
A.P. Green et al. (Puresyn Inc., Malvern, USA)

SESSION 10:
PRE-CLINICAL & CLINICAL TRIALS DEVELOPMENTS & LATE BREAKERS

Moderator:
Maurizio Zanetti (University of California, San Diego, USA)

11.35-12.05
KEYNOTE:
‘Plasmid DNA vaccination and assessment of immunogenicity in baboons’
Ronald Kennedy (Texas Tech University, USA)

12.05-12.25
‘Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers’
M. Mancini-Bourgine et al. (Pasteur Institute, Paris, France)

12.25-12.40
‘Truncated H9 influenza DNA vaccines’
Jim Robertson (NIBSC, Potters Bar, UK)

12.40-13.00
‘Multi-component DNA vaccines for biodefense’
Jay W. Hooper and Connie S. Schmaljohn (USAMRIID, Fort Detrick, USA)

SESSION 11:
Closing Plenary Lecture

Moderator:
David Weiner (University of Pennsylvania, USA)

13.00-13.30
KEYNOTE:
‘Immunotherapeutic vaccination – pros and cons’
Britta Wahren (Karolinska Institute, Stockholm, Sweden)

13.30
Closing Remarks by DNA VACCINES 2004 Conference Chairman:
David Weiner (University of Pennsylvania, USA)